– Product Launch Planned for September; ABRAXANE Now Approved in 40 Countries –
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE® IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment...
Over 30 Scientific Presentations at ASCO Exploring ABRAXANE’s Expanded Potential in Multiple Difficult-to-Treat Cancers
Clinical Data in Lung, Pancreatic, Melanoma, Ovarian, Head & Neck, Bladder and Triple-Negative Breast Cancers to be Presented at 46th Meeting of the American Society of Clinical Oncology
May 18, 2010 08:05 AM Eastern Daylight Time
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII) today announced that 32 scientific...
Genasense® Combined with Temodar® and Abraxane® Shows Preliminary Evidence of High Response Rates and Extended Survival in Patients with Advanced Melanoma
One-hour Infusion Schedule to be Tested in Next Cohort
BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GNTA) announced preliminary results that show a high objective response rate and potentially extended survival in an ongoing pilot study that incorporates the Company’s lead oncology product, Genasense®...
HOLLYWOOD, Florida -- March 13, 2009 -- Several new drugs could be added to the arsenal of weapons used to combat recurrent or metastatic non-small-cell lung cancer, doctors stated here at the National Comprehensive Cancer Network (NCCN) 14th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care.
More than a dozen cytotoxic and targeted agents can now be considered in battling the disease, noted David S. Ettinger, MD, Sidney Kimmel Comprehensive...
